Joseph Gut - thasso
Posted in Adverse Drug Reaction [ADR], New Safety Information, Regulatory Announcement, Thasso Post, Theragenomic Medicine
No Comments ↓
March 25, 2020 – The Covid-19 pandemic keeps the word abreast. Drastic measures have been and are being taken worldwide by governments, hospitals, healthcare care providers, and retiring homes in attempts to halt the spreading of Covid-19. Recently, there have been publications by Chinese clinical researchers in the Journal Cell Research and the International Journal of Antimicrob Agents indicating that both,
…
Joseph Gut - thasso
Posted in Adverse Drug Reaction [ADR], New Safety Information, Regulatory Announcement, Thasso Post, Theragenomic Medicine
1 Comment ↓
September 05, 2019 – An E-cigarette is a handheld battery-powered vaporizer that simulates smoking by providing some of the behavioral aspects of smoking, including the hand-to-mouth action of smoking, but without burning tobacco. Using an E-cigarette is known as “vaping” and the user is referred to as a “vaper.”
…
Joseph Gut - thasso
Posted in Adverse Drug Reaction [ADR], New Safety Information, Thasso Post, Theragenomic Medicine
No Comments ↓
February 17, 2019 – The unfortunate recognition of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a very rare form of a T-cell lymphoma, gains more momentum by the day. This is actually very positive a development, because it helps women who are getting breast implants for whatever reasons to better known associated health risks,
…
Joseph Gut - thasso
Posted in Adverse Drug Reaction [ADR], New Safety Information, Thasso Post, Theragenomic Medicine
No Comments ↓
June 08, 2019 – For some time now, Tofacitinib (Xeljanz) receives intense attention in the media, with regulatory authorities, and patients and treating physicians alike because of serious concerns of increased risk of blood clots in the lungs and increased mortality in patients treated for ulcerative colitis at the 10-mg twice-daily dose of Tofacitinib (Xeljanz).
…
Joseph Gut - thasso
Posted in Adverse Drug Reaction [ADR], New Safety Information, Regulatory Announcement, Thasso Post, Theragenomic Medicine
No Comments ↓
19 April 2019 – Alemtuzumab (Lemtrada) is used in the treatment of multiple sclerosis (MS). Moreover, Alemtuzumab, under the Tradenames of Campt, MabCampath and Campt-1H is on the markets for the treatment of chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma (CTCL),
…
Joseph Gut - thasso
Posted in In The Press, New Safety Information, Rare Diseases, Regulatory Announcement, Thasso Post, Theragenomic Medicine
No Comments ↓
January 09, 2019 – Women should be alerted: Is there a thing like breast implant associated cancer (BIA-ALCL)? Yes, there is. Not every woman with a breast implant will get it, however. In fact, BIA-ALCL seems to be a rather rare condition; unfortunately,
…
Joseph Gut - thasso
Posted in Adverse Drug Reaction [ADR], New Research, New Safety Information, Thasso Post, Theragenomic Medicine
No Comments ↓
October 21, 2018 – In a study published online September 13 in JAMA Oncology, the authors just reminded us of the fact that besides all hype about immune checkpoint inhibitors (ICIs) in the cancer therapy field,
…
Joseph Gut - thasso
Posted in Adverse Drug Reaction [ADR], New Safety Information, Rare Diseases, Thasso Post, Theragenomic Medicine
No Comments ↓
01 September 2018 – The American Food and Drug Administration (FDA) is warning that cases of a very rare but serious infection of the genitals and area around the genitals have been reported with the class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors.
…
Joseph Gut - thasso
Posted in Adverse Drug Reaction [ADR], New Safety Information, Regulatory Announcement, Thasso Post, Theragenomic Medicine
No Comments ↓
May 22, 2018 –The American Food and Drug Administration (FDA) just released a Safety Alert concerning serious neural tube defects that might arise in babies born to women who took HIV medications that contained the active ingredient Dolutegravir. Neural tube defects are birth defects that can occur early in pregnancy when the spinal cord,
…
Joseph Gut - thasso
Posted in Adverse Drug Reaction [ADR], New Safety Information, Thasso Post, Theragenomic Medicine
No Comments ↓
September 30, 2017 – Obeticholic acid (Ocaliva) was approved by the American Food & Drug Administration (FDA) in May 2016 for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adult patients with an inadequate response to UDCA,
…
Optional: Social Subscribe/Login
thasso: recent comments